- Amylyx Pharmaceuticals ( NASDAQ: AMLX ) has e ntered into a two-year agreement with the Sunnybrook Research Institute to develop drug candidates for neurodegenerative diseases.
- Specifically, the companies will work to identify candidates that inhibit the proteins Bax and Bak with high potency and specificity.
- The companies noted the partnership is specifically seeking candidates for amyotrophic lateral sclerosis (ALS).
- In an ALS mouse model, studies showed that targeted inhibition of Bax and Bak in ALS, led to the preservation of motor neurons, delayed symptom onset, and prolonged survival.
- At the end of the agreement, Amylyx ( AMLX ) has the option to license and develop candidates developed during the partnership.
- Bhavneesh Sharma said that that Amylyx ( AMLX ) is a buy ahead of a Sept. 29 U.S. FDA action date on AMX0035 for ALS.
For further details see:
Amylyx partners with Sunnybrook Research to identify neurodegenerative disease candidates